Tuesday, June 21, 2011
GTx Inc., of Memphis, Tenn., initiated a Phase IIb trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot (leuprolide acetate for depot suspension) for first-line treatment of advanced prostate cancer. The company said that the trial is an open-label study of 156 men with advanced prostate cancer. The primary endpoint is the proportion of patients who achieve castration by day 60.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.